The penetration of amphotericin B from an Intralipid formulation into fibrin loci in a rabbit model of candidiasis.
The kinetics of amphotericin B (AMB) concentrations in plasma and interstitial fluid were studied in an experimental model of Candida albicans infection in rabbits. Rabbits were infected by subcutaneously implanted fibrin clots containing the yeast. Three groups of five rabbits received a 4 mg kg-1 AMB infusion. AMB (Fungizone) was dissolved in 5% glucose (group I) or in 20% Intralipid at a final concentration of 1.5 (group II) or 3 mg mL-1 (group III). AMB was measured by liquid chromatography in plasma and in trypsin-dissolved fibrin clots up to 72 h after the infusion. No significant differences in AMB plasma and interstitial-fluid concentration kinetics between the three modes of administration were found. AMB penetration into fibrin clots was slow, with no significant differences between treatments. Thus, formulation of AMB in Intralipid does not modify either the drug's interstitial or plasma kinetics at equivalent doses.
Bouley
M
M
Departement de Pharmacotoxicologie, Hôpital Avicenne, Bobigny, France.
Tod
M
M
Chavanet
P
P
Petitjean
O
O
D000666:Amphotericin B / Q000097:blood / Q000493:pharmacokinetics*; D000818:Animals; D002176:Candida albicans; D002177:Candidiasis / Q000097:blood* / Q000139:chemically induced; D002851:Chromatography, High Pressure Liquid; D003198:Computer Simulation; D004195:Disease Models, Animal; D016503:Drug Delivery Systems; D005217:Fat Emulsions, Intravenous / Q000493:pharmacokinetics*; D005337:Fibrin / Q000378:metabolism*; D005947:Glucose / Q000493:pharmacokinetics; D008297:Male; D011817:Rabbits; D012867:Skin / Q000187:drug effects
D005217:Fat Emulsions, Intravenous; D000666:Amphotericin B; D005337:Fibrin; D005947:Glucose